Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial - Straus, David J; Długosz-Danecka, Monika; Connors, Joseph M; Alekseev, Sergey; Illés, Árpád; Picardi, Marco; Lech-Maranda, Ewa; Feldman, Tatyana; Smolewski, Piotr; Savage, Kerry J; Bartlett, Nancy L; Walewski, Jan; et al. (The Lancet. Haematology, 2021)
Keywords: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bleomycin - administration & dosage; Brentuximab Vedotin - administration & dosage; Doxorubicin - administration & dosage; Female; Follow-Up Studies; Hodgkin Disease - drug therapy; Hodgkin Disease - mortality; Hodgkin Disease - pathology; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Progression-Free Survival; Vinblastine - administration & dosage